Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 8/20 | 0.41 |
| ▸ | JAK1 | P23458 | 4/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21593165 | 0.89 | MAPT (0.46) | NR1H2ESR2MAP3K7MAPTACACB | |
| SCHEMBL21593208 | 0.85 | NR1H2 (0.56) | NR1H2ESR2MAPTJAK1MAPK14 | |
| SCHEMBL21593123 | 0.83 | NR1H2 (0.48) | NR1H2ESR2MAPTACACBMET | |
| SCHEMBL23326766 | 0.78 | NR1H2 (0.47) | NR1H2ESR2MAPTACACBMET | |
| SCHEMBL21593211 | 0.78 | ROCK2 (0.44) | NR1H2ESR2MAPTACACBBRAF | |
| SCHEMBL21593062 | 0.77 | ACACB (0.45) | NR1H2ESR2MAPTACACBJAK1 | |
| SCHEMBL21593114 | 0.76 | NR1H2 (0.44) | NR1H2ESR2MAPTACACBIGF1R | |
| SCHEMBL545512 | 0.75 | NR1H2 (0.54) | NR1H2ESR2BRAFKDR | |
| SCHEMBL23762242 | 0.75 | NR1H2 (0.43) | NR1H2ESR2MAPTACACBMET | |
| SCHEMBL25307616 | 0.74 | JAK1 (0.48) | NR1H2ESR2MAPTACACBJAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-08-19 | — | — | US | disclosed |
| WO-2019238628-A1 | AZAINDOLE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253568-A1 | AZAINDOLE DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | NR1H2 1422/4885ESR2 3940/4885MAP3K7 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.